Literature DB >> 11002240

Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge.

T A Gill1, P J Morley, C Sweet.   

Abstract

Five temperature-sensitive mutants (tsm9, tsm13, tsm20, tsm22, tsm30) of murine cytomegalovirus have been shown previously not to produce infectious virus in mice. In the present study, the stage at which these mutants are blocked in their replication in vitro was examined by transcriptional analysis of 4 temporally regulated marker genes (IE-1, E-1, gB and gH) using a semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) coupled with an electron microscopic analysis of infected cells incubated at permissive (33 degrees C) and non-permissive (39 and/or 40 degrees C) temperatures. Replication of tsm13 appeared to be blocked at a late phase of replication after capsid formation while the block appeared to be as early as the immediate-early phase in tsm22- infected cells. In contrast, mutants tsm9, tsm20 and tsm30 were blocked at a maturation step, probably of capsid formation, as gene transcription of all 4 marker genes occurred, albeit at reduced level, at 39 and 40 degrees C but no capsids or virions were produced at 40 degrees C. Replication and transcription of mutants tsm13, tsm20 and tsm30 were also examined in infected mice. Mutant tsm13 showed no gene expression or infectious virus while mutants tsm20 and tsm30 produced no infectious virus from days 3-60 post infection, except unusually for a low titre of tsm30 (2.3 x 10(3) pfu/ml) in salivary glands 21 days post infection. Gene transcription of all 4 marker genes was observed in one or more tissues (salivary glands, spleen, kidneys, liver, thymus, heart, lungs) at one or more time points (3, 7, 10, 14, 21 days post-infection) with both mutants. Mice became infected latently with tsm20 but not tsm30, and mice previously infected with tsm20 or tsm30 were protected against a sub-lethal challenge with virulent parental virus; tsm30 also protected against a lethal challenge. This suggests that these two mutants may be good model vaccines for further studies on the mechanism of protection induced and for identification of the ts genes. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11002240     DOI: 10.1002/1096-9071(200010)62:2<127::aid-jmv2>3.0.co;2-h

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.

Authors:  Christian Andreas Mohr; Jurica Arapovic; Hermine Mühlbach; Marc Panzer; Annelies Weyn; Lars Dölken; Astrid Krmpotic; David Voehringer; Zsolt Ruzsics; Ulrich Koszinowski; Torsten Sacher
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Authors:  Nicholas Farley; David I Bernstein; Fernando J Bravo; Julie Earwood; Nancy Sawtell; Rhonda D Cardin
Journal:  Antiviral Res       Date:  2010-02-16       Impact factor: 5.970

4.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

5.  Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.

Authors:  Luka Cicin-Sain; Ivan Bubić; Margit Schnee; Zsolt Ruzsics; Christian Mohr; Stipan Jonjić; Ulrich H Koszinowski
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.